Highlights from a recent BIO survey on therapeutic protein - Drug interactions

摘要

Therapeutic proteins (TPs, protein macromole-cules with molecular weights in excess of 1 kDa) are becoming increasingly important as therapeutic agents. A number of them have become the standard of care in several therapeutic areas, such as immunology and oncology. It is anticipated that these agents will continue to play an important role in the future as the investment and efforts into the discovery and development of biologies continue to increase. By the existing regulatory guidance, virtually every small molecule drug development program includes an evaluation of the potential drug-drug interactions (DDIs) for concomitant medications. The scientific and regulatory framework of DDI studies for small molecule drugs is well developed and has been applied for many years.